Dosimetric Comparison of Three Different Involved Nodal Irradiation Techniques for Stage II Hodgkin's Lymphoma Patients: Conventional Radiotherapy, Intensity-Modulated Radiotherapy, and Three-Dimensional Proton Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 1173-1180

  Chera, Bhishamjit S ^a   Rodriguez, Christina ^a   Morris, Christopher G ^a   Louis, Debbie ^b   Yeung, Daniel ^b   Li, Zuofeng ^b   Mendenhall, Nancy P ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Hodgkin's lymphoma; IMRT; Intensity modulated radiotherapy; Protons

Indexed keywords

CLINICAL OUTCOME; DOSE DISTRIBUTIONS; GRAY EQUIVALENT; HIGH DOSE; HODGKIN'S LYMPHOMA; IMRT; INTENSITY-MODULATED RADIOTHERAPY; LATE RADIATION EFFECTS; LUNG VOLUME; MEAN DOSE; NON-TARGETED; PLANNING TARGET VOLUMES; PROTON RADIOTHERAPY; RELATIVE REDUCTION; SALIVARY GLANDS; TREATMENT PLANS;

BIOLOGICAL ORGANS; COBALT; DOSIMETERS; DOSIMETRY; FLUORESCENT SCREENS; HISTOLOGY; ONCOLOGY; ONTOLOGY; PHYSICAL THERAPY; PROTONS; RADIATION EFFECTS; RADIOACTIVE TRACERS; RADIOTHERAPY; TELEVISION PICTURE TUBES;

THREE DIMENSIONAL;

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; PROTON;

ARTICLE; BREAST; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DISEASE SEVERITY; DOSIMETRY; HEART; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LUNG; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; SALIVARY GLAND; TARGET ORGAN; THYROID GLAND; TREATMENT PLANNING; WHOLE BODY RADIATION; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; MALE; MEDIASTINUM; METHODOLOGY; NECK; RADIATION EXPOSURE; RADIATION INJURY; RADIOTHERAPY; TUMOR VOLUME;

BREAST; FEMALE; HEART; HODGKIN DISEASE; HUMANS; LUNG; LYMPHATIC IRRADIATION; MALE; MEDIASTINUM; NECK; PROTONS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SALIVARY GLANDS; THYROID GLAND; TUMOR BURDEN;

EID: 70449721903     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.048     Document Type: Article

References (35)

1. Specht L., Gray R.G., Clarke M.J., et al., for the International Hodgkin's Disease Collaborative Group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16 (1998) 830-843
2. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 (2002) 2101-2108
3. Sklar C., Whitton J., Mertens A., et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85 (2000) 3227-3232
4. Hull M.C., Morris C.G., Pepine C.J., et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin's lymphoma treated with radiation therapy. JAMA 290 (2003) 2831-2837
5. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270 (1993) 1949-1955
6. Boivin J.F. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69 (1992) 1241-1247
7. Tucker M.A., Coleman C.N., Cox R.S., et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318 (1988) 76-81
8. Van Leeuwen F.E., Klokman W.J., Hagenbeek A., et al. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12 (1994) 312-325
9. Dores G.M., Metayer C., Curtis R.E., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20 (2002) 3484-3494
10. Van Leeuwen F.E., Klokman W.J., Veer M.B., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18 (2000) 487-497
11. Ng A.K., Bernardo M.V., Weller E., et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100 (2002) 1989-1996
12. Alterio D., Jereczek-Fossa B.A., Franchi B., et al. Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: A retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys 67 (2007) 144-150
13. Guerin S., Guibout C., Shamsaldin A., et al. Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: A case-control study. Int J Cancer 120 (2007) 96-102
14. Chronowski G.M., Wilder R.B., Tucker S.L., et al. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 36-43
15. Travis L.B., Hill D.A., Dores G.M., et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290 (2003) 465-475
16. Acharya S., Sarafoglou K., LaQuaglia M., et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 97 (2003) 2397-2403
17. Mauch P.M., Kalish L.A., Marcus K.C., et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1 (1995) 33-42
18. Ferme C., Eghbali H., Meerwaldt J.H., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357 (2007) 1916-1927
19. Bonadonna G., Bonfante V., Viviani S., et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22 (2004) 2835-2841
20. Engert A., Schiller P., Josting A., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 3601-3608
21. Noordijk E.M., Carde P., Dupouy N., et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24 (2006) 3128-3135
22. Duhmke E., Franklin J., Pfreundschuh M., et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19 (2001) 2905-2914
23. Hodgson D.C., Koh E.S., Tran T.H., et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110 (2007) 2576-2586
24. Koh E.S., Tran T.H., Heydarian M., et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: Reduction in normal tissue dose and second cancer risk. Radiat Oncol 2 (2007) 13
25. Lomax A.J., Bortfeld T., Goitein G., et al. A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol 51 (1999) 257-271
26. Goodman K.A., Toner S., Hunt M., et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62 (2005) 198-206
27. Girinsky T., Pichenot C., Beaudre A., et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?. Int J Radiat Oncol Biol Phys 64 (2006) 218-226
28. Ghalibafian M., Beaudre A., and Girinsky T. Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: Dose constraints to virtual volumes or to organs at risk?. Radiother Oncol 25 (2007) 5523-5524
29. Schneider U., Lomax A., and Lombriser N. Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation. Radiat Res 154 (2000) 382-388
30. Hall E.J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65 (2006) 1-7
31. Paganetti H., Bortfeld T., and Delaney T.F. Neutron dose in proton radiation therapy: In regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;65:1-7). Int J Radiat Oncol Biol Phys 66 (2006) 1594-1595
32. Gottschalk B. Neutron dose in scattered and scanned proton beams: In regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;65:1-7). Int J Radiat Oncol Biol Phys 66 (2006) 1594
33. Chung C.S., Yock T., Johnson J., et al. Proton radiation therapy and the incidence of secondary malignancies. [Abstract]. Int J Radiat Oncol Biol Phys 69 (2007) S178-S179
34. Claude L., Malet C., Pommier P., et al. Active breathing control for Hodgkin's disease in childhood and adolescence: Feasibility, advantages, and limits. Int J Radiat Oncol Biol Phys 67 (2007) 1470-1475
35. Stromberg J.S., Sharpe M.B., Kim L.H., et al. Active breathing control (ABC) for Hodgkin's disease: Reduction in normal tissue irradiation with deep inspiration and implications for treatment. Int J Radiat Oncol Biol Phys 48 (2000) 797-806